Six weeks after a positive readout in an expanded indication, the field force at a top five pharma chronic-disease brand reported something the forecast had not predicted. PCPs, the physicians who managed most of the newly eligible patients, were less receptive than the model expected. Standard quarterly tracking would eventually show whether the signal was real. By then, several months of PCP-targeted spend would already be committed.
That gap between a forecast and what reps hear in the room is one of the most common moments in a launch. It is also one of the easiest to misread. Here are five checks to run before the plan hardens, drawn from that case, one of five in Blind Spots in Launch Tracking, and from ZoomRx’s launch benchmark work.
A forecast-vs-field gap is any point in a launch where early feedback from the field force points in a different direction from the commercial forecast. It is a prompt to investigate. It does not by itself tell you which one is wrong.
In the case above, the team needed to know whether the issue was awareness, message relevance, or a deeper mismatch in how PCPs were responding to the brand.
Ask whether your current data reports PCPs and specialists separately, or as one HCP number.
In the chronic-disease case, ZoomRx found that PCPs and specialists were responding to different drivers. The aggregate HCP view had been masking that split. The audience-level read showed where the mismatch was coming from.
Low receptivity can come from physicians who have not heard the story, or from physicians who heard it and did not find it relevant. The fix for each is different.
The team’s weekly pulse tracked awareness, message recall, message effectiveness, prescribing likelihood, and motivation scores across PCPs and specialists. That combination, the core of promotional effectiveness tracking, shows which claims are actually moving behavior.
If the first post-launch read is quarterly, a signal that appears in week four may not be visible until month three or later.
The weekly cadence captured a sharp shift in message effectiveness that monthly tracking would likely have missed. In ZoomRx’s oncology launch benchmark, brand trajectories separated within three to six months of launch, so the window to act is short.
A forecast tells you what you expected. A benchmark tells you where comparable launches in the same therapy area actually sat at the same point.
In ZoomRx’s oncology launch benchmark of 44 brands, top performers averaged 75% aided awareness among target HCPs on Day 1, against 55% for poor performers, and the gap held through Month 48. Without a comparable-launch number, a soft field signal is hard to size.
List the commitments that will be hard to reverse before your next data point arrives: field deployment, media, message rotation.
With an audience-level weekly read, the chronic-disease team rebalanced PCP-targeted spend, rotated out weaker messages, and adjusted the plan before the mismatch compounded. The team protected launch momentum through Month 5 instead of discovering the issue months later.
|
Question |
If the answer is “no” |
|
Do we report PCP and specialist results separately? |
An aggregate view may be hiding an audience split |
|
Do we track message effectiveness, not just recall? |
You may not know which claims move behavior |
|
Is our first post-launch read fast enough to see a dip in months 1 to 3? |
Field feedback may be your only early signal |
|
Do we have a comparable-launch benchmark for Day 1 awareness? |
You cannot tell a soft signal from a normal one |
This was one of five launches in Blind Spots in Launch Tracking. The whitepaper sets out what each team believed going in, what the research found, and the decision that followed. Download the whitepaper →
To see how ZoomRx tracks a launch at the speed of these decisions, explore Launch Excellence and Pre-Launch and Launch Insights.